This invention is directed to spiroheterocyclic compounds of formula (I) wherein k, j, p, Q, R.sup.1, R.sup.3a, R.sup.3b, R.sup.3c, and R.sup.3d are as defined herein, as a stereoisomer, enantiomer, tautomer thereof or mixtures thereof; or a pharmaceutically acceptable salt, solvate or prodrug thereof, that are useful for the treatment and/or prevention of sodium channel-mediated diseases or conditions, such as pain. Pharmaceutical compositions comprising the compounds and methods of using the compounds are also disclosed.